Controlling bone disease improves survival of hemodialysis patients

July 02, 2008

Consistently maintaining certain blood levels of markers of bone metabolism and disease can prolong the lives of patients on hemodialysis, according to a study appearing in the September 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that keeping parathyroid hormone, calcium, and phosphorous levels in control is critically important for dialysis patients with chronic kidney disease (CKD).

Because mineral and bone disorder affects most patients with CKD, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) has set specific treatment targets for the indicators of this disorder--serum levels of parathyroid hormone, calcium, and phosphorous. While research has shown that elevations in these markers are associated with increased morbidity and mortality in dialysis patients, no study has investigated the long-term control of these parameters.

Dr. Mark Danese of Outcomes Insights, Inc. (Newbury Park, CA), and his colleagues, Dr. Vasily Belozeroff and Dr. Karen Smirnakis of Amgen, Inc. (Thousand Oaks, CA) and Dr. Kenneth Rothman of Research Triangle Institute (Research Triangle Park, NC), set out to determine whether more consistent control of parathyroid, calcium, and phosphorous levels within the KDOQI target ranges is associated with improved survival. The study was conducted among 24,803 adults initiating dialysis between 2000 and 2002. The researchers assessed whether survival was improved when patients were within the three target levels simultaneously. They also examined whether survival was improved when patients were within each of the three target levels for prolonged periods of time.

The researchers reported that it was important to meet as many of the targets as possible at any given time. Meeting the target for none of the three markers was associated with a 51% higher risk of death compared with patients who achieved targets simultaneously for all three markers. Patients meeting only one target had a 35% to 39% increased risk of death, and patients meeting any two targets had a 15% to 21% higher risk of death.

Dr. Danese and his team also found that the longer an individual met one or more targets, the better. For each marker, patients who achieved target values for less than three months had the highest risk of death compared with those who did so for one year. Compared with patients whose individual target levels were maintained for one year, patients with a parathyroid in target for less than three months had a 34% higher risk of death, patients with calcium in target for less than three months had a 16% higher risk of death, and patients with phosphorous in target for less than three months had a 62% higher risk of death.

The study also revealed that prior to the introduction of the KDOQI guidelines, relatively few patients either simultaneously met the targets for parathyroid hormone, calcium, and phosphorous or met any target for a full year. The authors discovered that levels of these parameters outside the KDOQI target ranges may account for as much as 20% of deaths in dialysis patients.

"These results suggest that there is a need for more consistent achievement of the KDOQI mineral metabolism targets, and that meeting this need may result in improved survival for incident hemodialysis patients," the authors write. They note that this can be a challenge, however, because the use of current treatment options often requires a tradeoff between controlling parathyroid hormone and controlling calcium and phosphorous.
-end-
This study was funded by Amgen, Inc. Drs. Belozeroff and Smirnakis are employed by Amgen, Inc. Drs. Danese and Rothman are consultants to Amgen, Inc.

The study, entitled "Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients," will be available online at http://cjasn.asnjournals.org/ beginning on Wednesday, July 2, 2008, and in print in the September issue of the CJASN.

The American Society of Nephrology (ASN) is a not-for-profit organization of 11,000 physicians and scientists dedicated to the study of nephrology and committed to providing a forum for the promulgation of information regarding the latest research and clinical findings on kidney diseases. ASN publishes CJASN, the Journal of the American Society of Nephrology (JASN), and the Nephrology Self-Assessment Program (NephSAP). In January 2009, the Society will launch ASN Kidney News, a newsmagazine for nephrologists, scientists, allied health professionals, and staff.

American Society of Nephrology

Related Chronic Kidney Disease Articles from Brightsurf:

How to ensure patients manage their chronic kidney disease
A Singapore study finds patients with chronic kidney disease need tailored nutrition guidance, as well as better communication with doctors and family support, to empower them to manage their condition.

Children with chronic kidney disease have outsized health burden
Chronically ill children with kidney disease may spend more time in the hospital, incur larger health care costs and have a higher risk of death compared to pediatric patients hospitalized for other chronic conditions, a new study suggests.

Your neighborhood may raise your risk of chronic kidney disease
A neighborhood's overall socioeconomic status, including income and education-level, may influence its residents' risk of chronic kidney disease, according to a study recently published in SSM Population Health by researchers from Drexel University's Dornsife School of Public Health.

These lifestyle choices can reduce the risk of chronic kidney disease
Active lifestyle choices such as eating vegetables, exercising and quitting smoking can reduce the risk of chronic kidney disease, a new study led by researchers at Karolinska Institutet in Sweden and Griffith University in Australia, reports.

SGLT2 inhibitors can slow progression of chronic kidney disease
The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

New study provides insight into chronic kidney disease
Researchers have further analyzed a known signaling pathway they believe brings them one step closer to understanding the complex physiology of patients with chronic kidney disease (CKD), which might provide a path to new treatment options.

Predicting risk of chronic kidney disease
Data from about 5 million people (with and without diabetes) in 28 countries were used to develop equations to help identify people at increased five-year risk of chronic kidney disease, defined as reduced estimated glomerular filtration rate (eGFR).

New tool predicts five-year risk of chronic kidney disease
A new risk calculator tool that uses a mix of variables including age, hypertension, and diabetes status can be used to predict accurately whether someone is likely to develop chronic kidney disease within five years.

Gap in care found for patients with chronic kidney disease: study
Millions of Canadians living with chronic kidney disease (CKD) may be going without critical testing from their primary care practitioners that would give them a good idea of the severity of the disease so they could intervene earlier with more appropriate care, according to a new study.

Read More: Chronic Kidney Disease News and Chronic Kidney Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.